Crohn’s Disease Clinical Trial Results

Browse clinical trials for Crohn’s Disease by phase, sponsor and reported results. Data from ClinicalTrials.gov.

• A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
  Phase 3 · Janssen Research & Development, LLC · Active, not recruiting · Feb 21, 2025
• A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Di
  Phase 2/3 · Janssen Research & Development, LLC · Active, not recruiting · May 7, 2025
• A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
  Phase 3 · Janssen Research & Development, LLC · Completed · Jul 30, 2026
• A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderate
  Phase 2 · Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Completed · Nov 1, 2023
• PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
  Phase 2 · Celularity Incorporated · Completed · Jul 7, 2026
• Loss of RESponse to Ustekinumab Treated by Dose Escalation
  Phase 3 · Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW · Completed · Apr 13, 2026
• A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moder
  Phase 2/3 · Pfizer · Terminated · Jul 1, 2026
• An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn'
  Phase 2/3 · AstraZeneca · Terminated · Jun 23, 2026
• ENhanced Recovery in CHildren Undergoing Surgery
  Phase 3 · Northwestern University · Completed · Jun 23, 2026
• Rifaximin in Patients With Diabetic Gastroparesis
  Phase 2 · Mayo Clinic · Terminated · Jun 22, 2026
• A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe
  Phase 3 · Takeda · Active, not recruiting · Jun 15, 2026
• A Dietary Intervention Study on the Microbiome in Crohn's Disease Patients
  N/A · Case Western Reserve University · Completed · Sep 19, 2024
• Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or C
  Phase 2 · Takeda · Completed · Mar 13, 2026
• Open-label Extension Study of Brazikumab in Crohn's Disease
  Phase 3 · AstraZeneca · Terminated · Apr 1, 2026
• A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
  Phase 2 · Teva Branded Pharmaceutical Products R&D, Inc. · Completed · Dec 5, 2025

Trials by condition

Lung CancerNon-Small Cell Lung CancerBreast CancerColorectal CancerGastric CancerLiver CancerPancreatic CancerProstate CancerOvarian CancerMelanomaLeukemiaLymphomaMultiple MyelomaGlioblastomaType 2 DiabetesObesityHypertensionHeart FailureAtrial FibrillationStrokeChronic Kidney DiseaseNASH / MASHAlzheimer’s DiseaseParkinson’s DiseaseMultiple SclerosisDepressionEpilepsyALSRheumatoid ArthritisPsoriasisAtopic DermatitisCrohn’s DiseaseUlcerative ColitisLupusAsthmaCOPD

All trials